Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Kowa Research Institute, Inc. |
---|---|
Information provided by: | Kowa Research Institute, Inc. |
ClinicalTrials.gov Identifier: | NCT00783081 |
The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.
Condition | Intervention | Phase |
---|---|---|
Intermittent Claudication |
Drug: K-134 Drug: Cilostazol 100 mg BID Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Estimated Enrollment: | 370 |
Study Start Date: | November 2008 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
low dose K-134: Experimental |
Drug: K-134
K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
|
mid dose K-134: Experimental |
Drug: K-134
K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
|
high dose K-134: Experimental |
Drug: K-134
K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
|
Comparator: Active Comparator |
Drug: Cilostazol 100 mg BID
Cilostazol 100mg BID for 26 weeks.
|
Placebo: Placebo Comparator |
Drug: Placebo
Placebo BID for 26 weeks.
|
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Colorado Prevention Center | 303-860-9900 |
United States, Arkansas | |
Not yet recruiting | |
Little Rock, Arkansas, United States | |
United States, California | |
Recruiting | |
Beverly Hills, California, United States | |
Recruiting | |
Santa Rosa, California, United States | |
Recruiting | |
Vista, California, United States | |
Not yet recruiting | |
Los Angeles, California, United States | |
Recruiting | |
Sacramento, California, United States | |
United States, Colorado | |
Recruiting | |
Aurora, Colorado, United States | |
United States, Florida | |
Not yet recruiting | |
Hialeah, Florida, United States | |
Recruiting | |
Clearwater, Florida, United States | |
Recruiting | |
Jacksonville, Florida, United States | |
Not yet recruiting | |
Sarasota, Florida, United States | |
Not yet recruiting | |
Pensacola, Florida, United States | |
United States, Illinois | |
Not yet recruiting | |
Chicago, Illinois, United States | |
United States, Indiana | |
Recruiting | |
Indianapolis, Indiana, United States | |
United States, Maine | |
Recruiting | |
Auburn, Maine, United States | |
United States, Missouri | |
Not yet recruiting | |
St Louis, Missouri, United States | |
United States, Oklahoma | |
Not yet recruiting | |
Oklahoma City, Oklahoma, United States | |
United States, Pennsylvania | |
Not yet recruiting | |
Danville, Pennsylvania, United States | |
United States, Rhode Island | |
Recruiting | |
Warwick, Rhode Island, United States | |
United States, Texas | |
Not yet recruiting | |
Houston, Texas, United States | |
Not yet recruiting | |
Amarillo, Texas, United States | |
United States, Virginia | |
Recruiting | |
Richmond, Virginia, United States | |
Recruiting | |
Norfolk, Virginia, United States |
Study Director: | Roger Morgan, M.D., FACS | Kowa Research Institute, Inc. |
Responsible Party: | Kowa Research Institute, Inc. ( Roger Morgan, M.D., FACS / Chief Medical Officer ) |
Study ID Numbers: | K-134-2.01US |
Study First Received: | October 30, 2008 |
Last Updated: | February 11, 2009 |
ClinicalTrials.gov Identifier: | NCT00783081 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Intermittent Claudication Peripheral Arterial Disease |
Arterial Occlusive Diseases Cilostazol Vasodilator Agents Vascular Diseases Anti-Asthmatic Agents Fibrinolytic Agents Arteriosclerosis Cardiovascular Agents |
Neuroprotective Agents Signs and Symptoms Fibrin Modulating Agents Phosphodiesterase Inhibitors Intermittent Claudication Platelet Aggregation Inhibitors Peripheral Nervous System Agents Bronchodilator Agents |
Respiratory System Agents Vasodilator Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Hematologic Agents Fibrinolytic Agents Arteriosclerosis Neuroprotective Agents Signs and Symptoms Fibrin Modulating Agents Therapeutic Uses Cardiovascular Diseases Arterial Occlusive Diseases Cilostazol |
Vascular Diseases Anti-Asthmatic Agents Enzyme Inhibitors Cardiovascular Agents Protective Agents Pharmacologic Actions Phosphodiesterase Inhibitors Autonomic Agents Intermittent Claudication Platelet Aggregation Inhibitors Peripheral Nervous System Agents Central Nervous System Agents Bronchodilator Agents |